Fragment-based Drug Discovery

Global Fragment-based Drug Discovery Market to Reach US$1.6 Billion by 2030

The global market for Fragment-based Drug Discovery estimated at US$977.0 Million in the year 2024, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 8.8% over the analysis period 2024-2030. Fragment Screening, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Fragment Optimization segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$270.8 Million While China is Forecast to Grow at 8.2% CAGR

The Fragment-based Drug Discovery market in the U.S. is estimated at US$270.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$248.7 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.8% CAGR.

Global Fragment-Based Drug Discovery Market - Key Trends & Drivers Summarized

Why Is Fragment-Based Drug Discovery a Game Changer in Pharmaceuticals?

Fragment-Based Drug Discovery (FBDD) has revolutionized pharmaceutical research by allowing scientists to develop drugs with higher specificity and efficacy. Unlike traditional drug discovery, FBDD involves screening smaller, “fragment” molecules that bind to target sites on proteins, which can then be optimized into potent drugs. This approach is particularly effective for complex disease targets such as cancer, where traditional methods have struggled. FBDD accelerates the drug discovery process and often leads to more viable drug candidates, making it a valuable approach for addressing unmet medical needs.

How Are Advanced Screening Techniques Enhancing FBDD?

The success of FBDD heavily relies on advanced screening technologies that enable the identification of fragment interactions with target proteins. Techniques like nuclear magnetic resonance (NMR), X-ray crystallography, and high-throughput screening allow researchers to visualize binding interactions in detail, facilitating more precise drug design. Recent advancements in AI-driven screening and computational modeling further optimize the FBDD process by predicting fragment-target binding more accurately. These innovations make FBDD a faster, more efficient, and cost-effective approach to drug discovery, appealing to pharmaceutical companies aiming for shorter development timelines.

What Role Does FBDD Play in Cancer and Neurological Research?

FBDD is particularly valuable in oncology and neurological research, where complex and traditionally “undruggable” targets are common. Cancer research, for example, benefits from FBDD’s ability to identify small molecule inhibitors that can precisely target and disrupt cancer cell growth mechanisms. Similarly, in neurological disorders, FBDD aids in discovering treatments that can cross the blood-brain barrier, addressing diseases like Alzheimer’s and Parkinson’s. The ability of FBDD to uncover novel therapeutic options for difficult-to-treat conditions makes it a growing area of focus in medical research.

What Drives Growth in the Fragment-Based Drug Discovery Market?

The growth in the FBDD market is driven by advancements in screening technologies, rising demand for targeted therapies, and its applications in challenging disease areas. New screening tools and AI-driven computational models enhance the efficiency of FBDD, attracting pharmaceutical companies looking for cost-effective drug discovery methods. The demand for targeted therapies, especially in oncology and neurology, further fuels FBDD adoption. Moreover, FBDD’s ability to identify novel treatment options for complex diseases provides a pathway for addressing unmet medical needs, making it a crucial area in modern pharmaceutical research.

SCOPE OF STUDY:

The report analyzes the Fragment-based Drug Discovery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Technology (Fragment Screening, Fragment Optimization); End-Use (Biopharmaceutical Companies, Academic & Research Institutions, Contract Research Organizations)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

• Akaal Pharma Pty. Ltd.
• Algorae Pharmaceuticals Ltd.
• Aragen Life Sciences Ltd.
• Beactica Therapeutics AB
• Carna Biosciences, Inc.
• Charles River Laboratories International, Inc.
• Crelux
• Evotec SE
• Marsala Biotech Inc.
• PsychoGenics, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.